Intra-Tumoral Heterogeneity of HER2, FGFR2, cMET and ATM in Gastric Cancer: Optimizing Personalized Healthcare through Innovative Pathological and Statistical Analysis
Published 2015 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Intra-Tumoral Heterogeneity of HER2, FGFR2, cMET and ATM in Gastric Cancer: Optimizing Personalized Healthcare through Innovative Pathological and Statistical Analysis
Authors
Keywords
-
Journal
PLoS One
Volume 10, Issue 11, Pages e0143207
Publisher
Public Library of Science (PLoS)
Online
2015-11-21
DOI
10.1371/journal.pone.0143207
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- FGFR2 amplification has prognostic significance in gastric cancer: results from a large international multicentre study
- (2014) X Su et al. BRITISH JOURNAL OF CANCER
- HER2, MET and FGFR2 oncogenic driver alterations define distinct molecular segments for targeted therapies in gastric carcinoma
- (2014) Y J Liu et al. BRITISH JOURNAL OF CANCER
- Low ATM protein expression and depletion of p53 correlates with olaparib sensitivity in gastric cancer cell lines
- (2014) Eiji Kubota et al. CELL CYCLE
- Cancer incidence and mortality worldwide: Sources, methods and major patterns in GLOBOCAN 2012
- (2014) Jacques Ferlay et al. INTERNATIONAL JOURNAL OF CANCER
- Volitinib, a potent and highly selective c-Met inhibitor, effectively blocks c-Met signaling and growth in c-MET amplified gastric cancer patient-derived tumor xenograft models
- (2014) Paul R. Gavine et al. Molecular Oncology
- Development of Serous Ovarian Cancer is Associated with the Expression of Homologous Recombination Pathway Proteins
- (2014) Qingqing Ye et al. PATHOLOGY & ONCOLOGY RESEARCH
- FGFR2 Gene Amplification in Gastric Cancer Predicts Sensitivity to the Selective FGFR Inhibitor AZD4547
- (2013) L. Xie et al. CLINICAL CANCER RESEARCH
- ATM-depletion in breast cancer cells confers sensitivity to PARP inhibition
- (2013) Maria Gilardini Montani et al. JOURNAL OF EXPERIMENTAL & CLINICAL CANCER RESEARCH
- RAD51C-Deficient Cancer Cells Are Highly Sensitive to the PARP Inhibitor Olaparib
- (2013) A. Min et al. MOLECULAR CANCER THERAPEUTICS
- Concordance of ATM (Ataxia Telangiectasia Mutated) Immunohistochemistry between Biopsy or Metastatic Tumor Samples and Primary Tumors in Gastric Cancer Patients
- (2013) Hee Sung Kim et al. PATHOBIOLOGY
- Biomarkers in precision therapy in colorectal cancer
- (2013) M. S. Reimers et al. Gastroenterology Report
- Cancer chromosomal instability: therapeutic and diagnostic challenges
- (2012) Nicholas McGranahan et al. EMBO REPORTS
- Intratumoral Heterogeneity Determines Discordant Results of Diagnostic Tests for Human Epidermal Growth Factor Receptor (HER) 2 in Gastric Cancer Specimens
- (2011) Jiyuan Yang et al. CELL BIOCHEMISTRY AND BIOPHYSICS
- Anti-MET Targeted Therapy Has Come of Age: The First Durable Complete Response with MetMAb in Metastatic Gastric Cancer
- (2011) Y. Feng et al. Cancer Discovery
- How Darwinian models inform therapeutic failure initiated by clonal heterogeneity in cancer medicine
- (2010) M Gerlinger et al. BRITISH JOURNAL OF CANCER
- Advanced gastric cancer – Slow but steady progress
- (2010) Derek G. Power et al. CANCER TREATMENT REVIEWS
- The role of HER2 in cancer therapy and targeted drug delivery
- (2010) Wanyi Tai et al. JOURNAL OF CONTROLLED RELEASE
Discover Peeref hubs
Discuss science. Find collaborators. Network.
Join a conversationAsk a Question. Answer a Question.
Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.
Get Started